Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese critically ill and morbidly obese critically ill patients

摘要

BackgroundDosing in obese critically ill patients is challenging due to pathophysiological changes derived from obesity and/or critical illness, and it remains fully unexplored. This study estimated the micafungin probability of reaching adequate 24-h area under the curve (AUC0–24h)/minimum inhibitory concentration (MIC) values against Candida spp. for an obeseonobese, critically illoncritically ill, large population.